Regulation of signaling pathways by Ampelopsin (Dihydromyricetin) in different cancers: Exploring the highways and byways less travelled

Basit Öğe Kaydı
dc.contributor.authorFayyaz, Sundas
dc.contributor.authorQureshi, Muhammad Zahid
dc.contributor.authorAlhewairini, Saleh S.
dc.contributor.authorAvnioğlu, Seda
dc.contributor.authorAttar, Rukset
dc.contributor.authorSabitaliyevich, Uteuliyev Yerzhan
dc.contributor.authorPawlak-Adamska, Edyta
dc.date.accessioned2021-02-19T21:16:34Z
dc.date.available2021-02-19T21:16:34Z
dc.date.issued2019
dc.departmentALKÜ
dc.descriptionAttar, Rukset/0000-0001-8770-9562; Pawlak, Edyta/0000-0002-0386-7940; Buha, Aleksandra/0000-0002-6942-7040; Adylova, Aima/0000-0002-8129-3209
dc.description.abstractAmpelopsin or Dihydromyricetin is gradually emerging as a high-quality natural product because of its ability to modulate wide-ranging signaling pathways. Ampelopsin (Dihydromyricetin) has been reported to effectively modulate growth factor receptor (VEGFR2 and PDGFR beta) mediated signaling, TRAIL/TRAIL-R pathway, JAK/STAT and mTOR-driven signaling in different cancers. Ampelopsin (Dihydromyricetin) has also been shown to exert inhibitory effects on the versatile regulators which trigger EMT (Epithelial-to-Mesenchymal Transition). Findings obtained from in-vitro studies are encouraging and there is a need to comprehensively analyze how Ampelopsin (Dihydromyricetin) inhibits tumor growth in different cancer models. Better knowledge of efficacy of Ampelopsin (Dihydromyricetin) in tumor bearing mice will be helpful in maximizing its translational potential.
dc.identifier.doi10.14715/cmb/2019.65.7.4
dc.identifier.endpage20en_US
dc.identifier.issn0145-5680
dc.identifier.issn1165-158X
dc.identifier.issue7en_US
dc.identifier.pmid31880533
dc.identifier.scopusqualityQ4
dc.identifier.startpage15en_US
dc.identifier.urihttps://doi.org/10.14715/cmb/2019.65.7.4
dc.identifier.urihttps://hdl.handle.net/20.500.12868/478
dc.identifier.volume65en_US
dc.identifier.wosWOS:000489886900004
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthor0-belirlenecek
dc.language.isoen
dc.publisherC M B Assoc
dc.relation.ispartofCellular And Molecular Biology
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAmpelopsin
dc.subjectDihydromyricetin
dc.subjectCancer
dc.subjectApoptosis
dc.subjectTherapy
dc.subjectSignaling
dc.titleRegulation of signaling pathways by Ampelopsin (Dihydromyricetin) in different cancers: Exploring the highways and byways less travelled
dc.typeReview Article

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu